Xerava
eravacycline
Table of contents
Overview
Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults. ‘Complicated’ means that the infection is difficult to treat because it has spread to the abdominal space.
Xerava contains the active substance eravacycline.
-
List item
Xerava : EPAR - Medicine overview (PDF/73.41 KB)
First published: 08/10/2018
EMA/521584/2018 -
-
List item
Xerava : EPAR - Risk-management-plan summary (PDF/198.19 KB)
First published: 08/10/2018
Last updated: 20/04/2023
Authorisation details
Product details | |
---|---|
Name |
Xerava
|
Agency product number |
EMEA/H/C/004237
|
Active substance |
eravacycline
|
International non-proprietary name (INN) or common name |
eravacycline
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
J01AA
|
Publication details | |
---|---|
Marketing-authorisation holder |
PAION Deutschland GmbH
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
20/09/2018
|
Contact address |
Heussstraße 25 |
Product information
11/05/2023 Xerava - EMEA/H/C/004237 - IAIN/0024
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.